.25mg of semaglutide 0.25mg for Weight Loss: Physician-Led Support | Desert Mobile Medical including heart disease Obesity | Novo Nordisk U.S.

Consult your branchs specific medical guidance

Takes about 2 minutes

COTA: cotadutida

Metabolic Flexibility GIP and glucagon receptor activation complements GLP-1 appetite suppression with enhanced energy expenditure and improved lipid metabolism signalling

The Medicines and Healthcare products Regulatory Agency predicts that supply issues are unlikely to resolve before the end of 2024

Study population The study population included adults (aged 18 years) with body mass index (BMI) 27 kg/m with 1 obesity-related complication or BMI 30 kg/m, who initiated tirzepatide (Zepbound ) or semaglutide (Wegovy ) for obesity management between December 1, 2023, and June 30, 2024